Mark Anderson
10Patents
3h-index
35Co-inventors
56Inventor score
Filing activity: Dec 4, 2009 → Apr 29, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8624027B2 | Combination therapy for treating cancer and diagnostic assays for use therein | Chemistry; Metallurgy | 16 | Active |
| US10383948B2 | Anti-cMet antibody drug conjugates and methods for their use | Human Necessities | 4 | Active |
| US9725515B2 | Prolactin receptor binding proteins and uses thereof | Emerging Cross-Sectional Technologies | 3 | Active |
| US10662235B2 | Cysteine engineered fibronectin type III domain binding molecules | Chemistry; Metallurgy | 2 | Active |
| US9725497B2 | EGFR and C-Met fibronectin type III domain binding molecules | Chemistry; Metallurgy | 2 | Active |
| US10112999B2 | Anti-PRLR antibody-drug conjugates (ADC) and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US10184003B2 | Prolactin receptor binding proteins and uses thereof | Emerging Cross-Sectional Technologies | 1 | Active |
| US11633497B2 | Anti-c-Met antibody drug conjugates | Chemistry; Metallurgy | 0 | Active |
| US12304939B2 | EGFR and C-met fibronectin type III domain binding molecules | Chemistry; Metallurgy | 0 | Active |
| US10954284B2 | EGFR and c-Met fibronectin type III domain binding molecules | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.